Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants

被引:11
|
作者
Kamkamidze, G
Sullivan, T
Charbonneau, T
机构
[1] New York State Dept Hlth, Wadsworth Ctr Labs & Res, Griffin Labs, Pediat HIV PCR Testing Lab, Albany, NY 12201 USA
[2] AIDS & Clin Immunol Rs Ctr, Tbilisi, Georgia
基金
美国国家卫生研究院;
关键词
human immunodeficiency virus type 1; codon; 215; resistance; infants;
D O I
10.1016/S1386-6532(01)00178-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The nucleoside reverse transcriptase inhibitor Zidovudine (ZDV) decreases mother to child transmission of HIV infection. Nevertheless, significant proportions of mothers who are treated during pregnancy with ZDV still transmit the virus. Along with other factors, failure of ZDV prophylaxis may be due to maternal infection with ZDV-resistant strains and their consequent vertical transmission. Objectives: The purpose of the study was to investigate the occurrence of mutations at codon 215 in HIV-1 infected infants and its association with clinical status and virological parameters. Study design: The cohort consisted of 49 HIV-1 infected infants. Mononuclear cell DNA was isolated from whole blood and served as the input DNA for both a qualitative DNA PCR and the codon 215 assay (nested PCR). HIV-1 viral load (RNA PCR) was measured in plasma by the Roche Amplicor (TM) Monitor assay. Results: Twelve of the 49 (24.5%) demonstrated viral strains with mutation at codon 215. A significant difference was found in infants born between 1992 and 1994 (6.3%) compared to those born in 1998-1999 (33.3%). Furthermore, in those infants born in 1998-1999, there was a trend toward an increase in the frequency of zidovudine resistant mutations at codon 215 corresponding to an increase in maternal zidovudine treatment. The mixture of wild and mutant HIV-1 strains was detected in two of 14 infants (14.3%) with a low viral load ( < 750 000 c/ml) compared to nine of 19 (47.4%) infants with extremely high levels of HIV-1 RNA concentration ( > 750 000 c/ml). Only two of 33 tested infants were HIV symptomatic and in both, a mixture of wild and mutant HIV-I strains was detected. In both infants, the viral load was > 750000 c/ml. Conclusions: This study showed that the overall frequency of ZDV resistant strains in infants born in 1998-1999 was significantly higher than that found in infant samples from 1992 to 1994. By 1998, the standard of care for mothers known to be infected with HIV was treatment with either monotherapy using ZDV or combined therapy using a variety of antiretroviral agents including ZDV. Although the exact role of ZDV resistance in limiting the effectiveness of therapies aimed at blocking vertical transmission of HIV remains to be defined, it is clear that drug resistant strains of HIV are occurring more frequently in all types of HIV infection, including infants. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [1] Prevalence of atypical mutations at codon 215 of HIV-1 reverse transcriptase
    Cane, P
    Rehman, Y
    Porter, K
    Pillay, D
    ANTIVIRAL THERAPY, 2002, 7 : S60 - S60
  • [2] HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: Immunologic and virologic responses to zidovudine
    Rey, D
    Hughes, M
    Pi, JT
    Winters, M
    Merigan, TC
    Katzenstein, DA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (03): : 203 - 208
  • [3] HIV-1 REVERSE-TRANSCRIPTASE CODON-215 MUTATION AND CLINICAL OUTCOME IN CHILDREN TREATED WITH ZIDOVUDINE
    PRINCIPI, N
    MARCHISIO, P
    DEPASQUALE, MP
    MASSIRONI, E
    TORNAGHI, R
    VAGO, T
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (06) : 721 - 726
  • [4] DETECTION OF REVERSE-TRANSCRIPTASE CODON-215 AZIDOTHYMIDINE RESISTANCE MUTATIONS IN HIV-INFECTED CHILDREN
    ZHOU, LX
    NELSON, RP
    BRADLEY, W
    DAY, NK
    GOOD, RA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) : 245 - 245
  • [5] Rate of development of mutation at codon 215 of HIV-1 reverse transcriptase and its predictive factors at the time of initiation of zidovudine therapy
    Leal, M
    Rey, C
    Torres, Y
    Relimpio, F
    Pino, R
    Lissen, E
    SanchezQuijano, A
    Luque, F
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (06) : 476 - 480
  • [6] Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine
    Orlandi, P
    Cancrini, C
    Scaccia, S
    Romiti, ML
    Livadiotti, S
    Gattinara, GC
    Angelini, F
    Cox, S
    Rossi, P
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 19 (03) : 230 - 237
  • [7] HIV-1 reverse transcriptase inhibitors
    El Safadi, Yazan
    Vivet-Boudou, Valerie
    Marquet, Roland
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2007, 75 (04) : 723 - 737
  • [8] HIV-1 reverse transcriptase inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (03) : 122 - 122
  • [9] HIV-1 reverse transcriptase inhibitors
    Yazan El Safadi
    Valérie Vivet-Boudou
    Roland Marquet
    Applied Microbiology and Biotechnology, 2007, 75 : 723 - 737
  • [10] Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase
    Barnard, John P.
    Huber, Kelly D.
    Sluis-Cremer, Nicolas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)